TARGET
saveCD20
B-cell antigen; target of rituximab and obinutuzumab.
also known as: ms4a1, b-lymphocyte antigen cd20
🐶 often sniffed alongside
top 8- tagRecall3 co-mentions · 3 sources
- tagOncology3 co-mentions · 1 sources
- tagMonoclonal Antibody3 co-mentions · 3 sources
- tagCLL2 co-mentions · 1 sources
- tagCD191 co-mentions · 1 sources
- tagDLBCL1 co-mentions · 1 sources
- tagCD221 co-mentions · 1 sources
- drugAnti-CD19/CD20/CD22 CAR T-cells1 co-mentions · 1 sources
drugs
0
catalysts
0
news
18
companies
0
Top drugs
no drugs tagged with this interest yet
🐶 Top companies
no companies tagged with this interest yet
Recent catalysts
no catalysts tagged with this interest yet
Recent news
view all →- 6 potential blockbusters that could pave China’s path to 2030 ambitionsbiospace · 15d ago
- Gilead reveals partial clinical hold on 2 CAR-T cell therapy trialsfiercebiotech · 21d ago
- Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T assetbiospace · 28d ago
- Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyoutfiercebiotech · 28d ago
- Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approachesfiercebiotech · 29d ago
- How Abogen went from COVID hype to a $7.8B Novartis dealbiospace · 1mo ago
- GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750Mbiospace · 2mo ago
- The hidden scale-out problem behind CAR-T’s growthbiopharma dive · 2mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that